BioCentury
ARTICLE | Emerging Company Profile

Actelion: Experience counts in Europe

June 15, 1998 7:00 AM UTC

In Europe, sound and experienced management teams for start-up biotechnology companies run scarce. Actelion, founded in December 1997, attracted venture capital quickly, probably because of the collective scientific, clinical and business experience of its founders, said founder and CEO Thomas Widmann.

The company discovers and develops small molecule therapeutics for conditions that involve the vascular endothelium. Its founders include experts in endothelium research as well as R&D and clinical development managers with large pharma company experience. The team plans to build a company capable of taking products in a specific field rapidly from discovery to clinical validity...